Secondary immunodeficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:15:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Secondary immunodeficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy https://clinicaltrials.eu/trial/study-of-human-normal-immunoglobulin-and-teclistamab-for-infection-prevention-in-adults-with-multiple-myeloma-receiving-b-cell-maturation-antigen-therapy/ Wed, 29 Apr 2026 15:06:34 +0000 https://clinicaltrials.eu/trial/study-of-human-normal-immunoglobulin-and-teclistamab-for-infection-prevention-in-adults-with-multiple-myeloma-receiving-b-cell-maturation-antigen-therapy/ This study focuses on patients with Multiple Myeloma who are receiving treatment with teclistamab, a medication that targets specific proteins on cancer cells. The study aims to evaluate whether giving preventive treatment with immune globulin infusion (a solution containing antibodies) early in the course of cancer therapy is more effective than waiting to give it only after infections occur.

The treatment involves two medications: TECVAYLI (teclistamab), which is given as an injection under the skin, and KIOVIG, which is given through an intravenous infusion. TECVAYLI is a specialized antibody that helps the immune system fight cancer cells, while KIOVIG contains antibodies that help prevent infections in patients whose immune systems are weakened by cancer treatment.

During the study, patients will receive their regular cancer treatment with TECVAYLI and will be divided into two groups. One group will receive KIOVIG preventively from the start of their cancer treatment, while the other group will only receive KIOVIG if they develop infections. The study will track how well these different approaches work in preventing serious infections over a period of 12 months.

]]>